Provided by Tiger Fintech (Singapore) Pte. Ltd.

Protalix BioTherapeutics

2.85
-0.0900-3.06%
Post-market: 2.850.00000.00%19:57 EDT
Volume:797.51K
Turnover:2.31M
Market Cap:222.39M
PE:77.76
High:3.04
Open:2.99
Low:2.84
Close:2.94
Loading ...

Company Profile

Company Name:
Protalix BioTherapeutics
Exchange:
AMEX
Establishment Date:
- -
Employees:
213
Office Location:
2 University Plaza,Suite 100,Hackensack,New Jersey,United States
Zip Code:
07601
Fax:
- -
Introduction:
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Directors

Name
Position
Dror Bashan
President and Chief Executive Officer, Director
Zeev Bronfeld
Chairman of the Board
Aharon Schwartz
Director
Amos Bar Shalev
Director
Gwen A. Melincoff
Director
Pol F. Boudes
Director
Shmuel Ben Zvi
Director

Shareholders

Name
Position
Dror Bashan
President and Chief Executive Officer, Director
Eyal Rubin
Sr. Vice President, Chief Financial Officer, Treasurer and Secretary
Yael Hayon
Vice President, Research and Development
Yaron Naos
Sr. Vice President, Operations